VEGF Binding to the VEGFR2 Assessed in Real-Time in Living Cells with NanoBRET™ Assay

Growth factors stimulate receptor tyrosine kinases (RTK) which results in regulation of cell proliferation, growth, differentiation, and cell death. Therefore, RTKs are an attractive anti-cancer target as aberrant RTK-signaling promotes cancer. Expansion of pharmaceutical RTK-inhibitors needs methods which characterize receptor-ligand interaction and identify the inhibitors of the interaction.

Using an innovative technique, the vascular endothelial growth factor (VEGF) was tagged at a single locus with the fluorophore TMR. The labeled ligand was used in conjugation with HEK293 cells exhibiting the RTK VEGF-receptor 2 (VEGFR2) attached to the NanoLuc® luciferase. Upon interaction between receptor and ligand, bioluminescence resonance energy transfer (BRET) between luciferase and fluorophore occurs.

The PHERAstar microplate reader obtained the signal of luciferase and fluorophore in parallel. In this manner, not only the pKi of a VEGF-inhibitor was measured, but also the time-course of inhibition and binding was observed.

Read the full article including the methods, results and discussion.

NanoBRET assay quantitatively evaluates VEGF binding to the VEGFR2 in real time in living cells

About BMG Labtech

BMG LABTECH has been committed to producing microplate readers for more than twenty years. By focusing on the needs of the scientific community, the company’s innovative microplate readers have earned the company the reputation of being a technology leader in the field.

BMG LABTECH has developed a wide range of dedicated and multi-mode microplate readers for life sciences applications and high-throughput screening.

All BMG LABTECH microplate readers are "Made in Germany" and are conceived, developed, assembled, and tested entirely at our headquarters in Germany.

Since our establishment in Offenburg, Germany in 1989, BMG LABTECH has expanded to offer a worldwide sales and support network with offices in the USA, UK, Australia, Japan and France. Our subsidiaries, regional offices and distributors are committed to bringing you innovative microplate reader technology with the quality and reliability you expect from a German company.

Our staff includes engineers and scientists from the fields of biology, biochemistry, analytical chemistry, and physics.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Apr 3, 2020 at 1:41 PM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    BMG LABTECH GmbH. (2020, April 03). VEGF Binding to the VEGFR2 Assessed in Real-Time in Living Cells with NanoBRET™ Assay. News-Medical. Retrieved on October 31, 2024 from https://www.news-medical.net/whitepaper/20180731/VEGF-Binding-to-the-VEGFR2-Assessed-in-Real-Time-in-Living-Cells-with-NanoBRET-Assay.aspx.

  • MLA

    BMG LABTECH GmbH. "VEGF Binding to the VEGFR2 Assessed in Real-Time in Living Cells with NanoBRET™ Assay". News-Medical. 31 October 2024. <https://www.news-medical.net/whitepaper/20180731/VEGF-Binding-to-the-VEGFR2-Assessed-in-Real-Time-in-Living-Cells-with-NanoBRET-Assay.aspx>.

  • Chicago

    BMG LABTECH GmbH. "VEGF Binding to the VEGFR2 Assessed in Real-Time in Living Cells with NanoBRET™ Assay". News-Medical. https://www.news-medical.net/whitepaper/20180731/VEGF-Binding-to-the-VEGFR2-Assessed-in-Real-Time-in-Living-Cells-with-NanoBRET-Assay.aspx. (accessed October 31, 2024).

  • Harvard

    BMG LABTECH GmbH. 2020. VEGF Binding to the VEGFR2 Assessed in Real-Time in Living Cells with NanoBRET™ Assay. News-Medical, viewed 31 October 2024, https://www.news-medical.net/whitepaper/20180731/VEGF-Binding-to-the-VEGFR2-Assessed-in-Real-Time-in-Living-Cells-with-NanoBRET-Assay.aspx.

Other White Papers by this Supplier

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.